AN2 Therapeutics, Inc. (ANTX) vs ProQR Therapeutics N.V. (PRQR)
A side-by-side comparison of AN2 Therapeutics, Inc. and ProQR Therapeutics N.V. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
ANTX
AN2 Therapeutics, Inc.
$5.07HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
PRQR
ProQR Therapeutics N.V.
$1.65HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — ANTX vs PRQR
growth of $100 · dividends reinvested · last 5yANTX -63.6% (-18.3%/yr)PRQR +77.7% (+12.2%/yr)PRQR compounded faster over this window
ANTX PRQR
ANTX vs PRQR: by the numbers
- •ANTX is the larger company ($183M vs $174M market cap).
- •Both run net losses; ANTX's is the smaller (0.00% vs -229.20% net margin).
Metrics side by side
Valuation
| Metric | ANTX | PRQR |
|---|---|---|
| P/S ratio | N/A | 8.09 |
| P/B ratio | 2.41 | 1.91 |
Profitability
| Metric | ANTX | PRQR |
|---|---|---|
| Gross margin | 0.00% | 83.01% |
| Operating margin | 0.00% | -275.91% |
| Net margin | 0.00% | -229.20% |
| ROE | -47.78% | -54.27% |
| ROIC | -51.01% | -42.61% |
Growth (annualized)
| Metric | ANTX | PRQR |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 94.34% |
| Total return CAGR (5Y) | N/A | -26.23% |
Go deeper
Dig into the metrics
AN2 Therapeutics ROEProQR Therapeutics ROEAN2 Therapeutics operating marginProQR Therapeutics operating marginAN2 Therapeutics revenue growthProQR Therapeutics revenue growthAN2 Therapeutics free cash flowProQR Therapeutics free cash flow
AN2 Therapeutics & ProQR Therapeutics appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.